RxDoctor Payments Data

Timothy Carter, MD

Neurology · Melbourne, FLNPI 1154311652

Payments from drug & device makers

$6,161in general payments, 2019–2025

Across 334 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$698
  • Novartis$675
  • Intuitive Surgical$549
  • EMD Serono, Inc.$359
  • Teva Pharmaceuticals USA, Inc.$324
  • Amgen$270
  • plus $3K from 38 others

What the payments were for

  • Speaking & faculty fees$1132%
  • Travel & lodging$5499%
  • Food & beverage$5,46889%
  • Education$311%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,161 in reported general payments places this provider in the 55th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$270,273
Medicare patients
491
Services billed
19,110

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5018$235,004
Kesimpta PenOfatumumab12$118,566
Nurtec OdtRimegepant Sulfate46$51,561
NuplazidPimavanserin Tartrate11$45,018
QuliptaAtogepant23$26,033
UbrelvyUbrogepant13$14,685
BotoxOnabotulinumtoxina11$14,173
Ajovy SyringeFremanezumab-Vfrm18$13,128
Aimovig AutoinjectorErenumab-Aooe11$12,129
Carbidopa-LevodopaCarbidopa/Levodopa160$7,927
Emgality PenGalcanezumab-Gnlm11$7,642
Gabapentin341$6,790
Lacosamide16$5,674
Levetiracetam167$4,331
Pyridostigmine Bromide41$3,954

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$54$235,00418 claims
AbbVieQulipta, Ubrelvy, Botox$698$54,89147 claims
Acadia Pharmaceuticals IncNuplazid$143$45,01811 claims
Upsher-smith Laboratories LLCTopiramate$59$88384 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,434 neurology providers in Florida.

Other neurology in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →